Zevra agrees to sell SDX portfolio to Commave Therapeutics for $50 million

Zevra Therapeutics, Inc. (Nasdaq: ZVRA) agreed on March 16, 2026 to sell its serdexmethylphenidate (SDX) portfolio to Commave Therapeutics SA for $50 million. The portfolio includes AZSTARYS and KP1077. The announcement, made in a press release filed with an 8-K, also settles a lawsuit between the two companies and says Zevra had already repaid a $63 million term loan.

The buyer and the history

Zevra and Commave had been partners since 2019, when Zevra granted Commave an exclusive license to certain SDX products. In 2024, Commave started litigation against Zevra in the Delaware Chancery Court. The release says that, as part of the purchase agreement, the parties agreed to settle that dispute. It does not describe the settlement terms, and it does not say whether either side pays anything under the settlement.

Zevra's chief executive, Neil F. McFarlane, called the agreement "mutually beneficial" and said the company has enjoyed a productive partnership with Commave over the years. The release does not compare the price with the sales the portfolio has produced.

The term loan

Before signing, the company repaid the principal balance of its $63 million term loan in full. The release calls the result "a strong, debt-free balance sheet and enhanced financial and strategic flexibility." That is the company's own description. The release does not name the lender, say how the repayment was funded, or describe any interest or fees paid on the loan.

The release gives the loan principal as $63 million and the sale price as $50 million, and it does not link the two.

The recent numbers

The annual report on Form 10-K for the year ended December 31, 2025, filed on March 9, 2026, reports net income of $83.2 million for 2025, against a net loss of $105.5 million for 2024. Cash used in operations was $69.7 million in 2024 and $1.6 million in 2025. Year-end 2024 cash and cash equivalents were $33.8 million, with short-term investments of $35.7 million.

Reported profit and cash used in operations moved sharply between the two years. The release does not discuss these results or say what drove either movement, so the press release gives a reader no way to judge the SDX sale against the company's finances.

What the company keeps

The release describes Zevra as a commercial-stage company with a late-stage pipeline. Its lead product is marketed in the United States for Niemann-Pick disease type C, which the release describes as a rare, progressive neurodegenerative disease. The company says the commercialization of that product provides a strong corporate foundation.

The release says the company is focused on geographic expansion opportunities and on progressing its pipeline toward key milestones. It names no pipeline program, no milestone and no date. It also does not say what share of the company's revenue came from SDX products, so readers cannot measure how much of the business is being sold.

Government pricing obligations

The annual report's risk factors say Zevra participates in the Medicaid Drug Rebate Program and in the 340B drug pricing program. The filing says that failure to comply with reporting and payment obligations could lead to additional reimbursement requirements, penalties, sanctions and fines. Those passages describe the company's obligations in general terms and do not tie them to the SDX products.

What the release leaves open

The release gives no closing date, no conditions for the sale and no description of how the $50 million will be paid. It does not state the terms of the Chancery settlement, the expenses tied to the litigation or any financial effect of the settlement on the company. It names no financial adviser and no law firm for either side.

The headline terms are a $50 million sale, a settled lawsuit and a repaid loan. The release supplies few details behind any of the three.

Report an error

Companies in this story

ZVRAZevra Therapeutics, Inc.NASDAQ · United StatesOpen the starter desk